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cell transcription factors (SOX2, OCT4,
BMI1) and clinical implication
Samantha Kaufhold1, Hermes Garbán2* and Benjamin Bonavida1*
Abstract
The transcription factor Yin Yang 1 (YY1) is frequently overexpressed in cancerous tissues compared to normal
tissues and has regulatory roles in cell proliferation, cell viability, epithelial-mesenchymal transition, metastasis and
drug/immune resistance. YY1 shares many properties with cancer stem cells (CSCs) that drive tumorigenesis,
metastasis and drug resistance and are regulated by overexpression of certain transcription factors, including SOX2,
OCT4 (POU5F1), BMI1 and NANOG. Based on these similarities, it was expected that YY1 expression would be
associated with SOX2, OCT4, BMI1, and NANOG’s expressions and activities. Data mining from the proteomic
tissue-based datasets from the Human Protein Atlas were used for protein expression patterns of YY1 and the four
CSC markers in 17 types of cancer, including both solid and hematological malignancies. A close association was
revealed between the frequency of expressions of YY1 and SOX2 as well as SOX2 and OCT4 in all cancers analyzed.
Two types of dynamics were identified based on the nature of their association, namely, inverse or direct, between
YY1 and SOX2. These two dynamics define distinctive patterns of BMI1 and OCT4 expressions. The relationship
between YY1 and SOX2 expressions as well as the expressions of BMI1 and OCT4 resulted in the classification of
four groups of cancers with distinct molecular signatures: 1) Prostate, lung, cervical, endometrial, ovarian and
glioma cancers (YY1loSOX2hiBMI1hiOCT4hi) 2) Skin, testis and breast cancers (YY1hiSOX2loBMI1hiOCT4hi) 3) Liver,
stomach, renal, pancreatic and urothelial cancers (YY1loSOX2loBMI1hiOCT4hi) and 4) Colorectal cancer, lymphoma
and melanoma (YY1hiSOX2hiBMI1loOCT4hi). A regulatory loop is proposed consisting of the cross-talk between the
NF-kB/PI3K/AKT pathways and the downstream inter-regulation of target gene products YY1, OCT4, SOX2 and BMI1.
Keywords: BMI1, Cancer stem cells, NANOG, OCT4, SOX2, Yin Yang 1
Background
General properties of cancer stem cells (CSCs)
Drug resistance and metastatic spread are two key char-
acteristics of tumors that make cancer so difficult to
eradicate. Tumors are comprised of heterogeneous cell
subpopulations, and these subsets respond distinctly and
differently to various therapeutics [1]. One subset of
these cells consists of cancer stem cells (CSCs), which
are largely similar to normal stem cells with respect to
both their behavior and their regulation [2]. CSCs are
pluripotent, capable of self-renewal, highly resistant to
cytotoxic therapies, and drive tumorigenesis.
In addition to different cellular responses, adaptive
changes like the epithelial to mesenchymal transition
(EMT) exacerbate metastatic spread and drug resistance.
EMT is the process by which epithelial cells lose their
apico-basolateral polarity to become migratory mesen-
chymal cells. This process is crucial to embryonic differ-
entiation but is dysregulated in cancer, affording tumor
cells invasive and migratory properties. EMT has been
shown to cause reversion to a CSC-like phenotype, link-
ing CSCs, EMT and drug resistance [3, 4].
Clearly, better molecular and biochemical understand-
ings of the phenotypic and functional properties of CSCs
will help in the development of novel and specific tar-
geted therapeutics to eradicate CSCs. Thus, these should
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reduce the inherent resistance and relapses and should
prolong survival. Below, we briefly present reported
studies on the various regulatory factors in the develop-
ment of CSCs.
CSC markers
The sex determining region Y-box 2 (SOX2), POU class
5 homeobox 1 (POU5F1), B cell-specific Moloney mur-
ine leukemia virus insertion site 1 (BMI1) and Nanog
homeobox (NANOG) genes are four genes encoding
transcription factors that have been reported to be in-
volved in the regulation of CSCs. SOX2, Octamer-
binding transcription factor 4 (OCT4) (the transcription
factor encoded by POU5F1, also known as POU5F1) and
NANOG make up the core transcriptional network re-
sponsible for the regulation of stem cell self-renewal and
pluripotency [5].
SOX2
a) General properties of SOX2
The SOX2 gene is located on chromosome 3q26.3-
q27 [6, 7]. The SOX2 protein is composed of 317
amino acids and has a mass of 34.3 kDa [8].
Originally characterized in 1994, SOX2 is a member
of the SOXB1 family of transcription factors, and its
three primary domains are an N-terminal domain, a
high-mobility group (HMG) domain, and a transac-
tivation domain [9]. Protein partners, nuclear import
signals, and nuclear export signals bind the HMG
domain, while the C-terminal transactivation domain
is responsible for promoter binding, causing the acti-
vation or repression of target genes [10].
b) SOX2 expression in various cancers
SOX2 is expressed in neural stem cells [11], breast
stem cells [12], and stem populations in the liver,
pancreas, and stomach [13]. SOX2 overexpression in
recurrent prostate cancer tissues has been reported
[14]. SOX2 is likewise overexpressed in head and
neck squamous cell carcinoma [15]. Bioinformatics
analysis showed SOX2 overexpression in 7/36 solid
tumors analyzed [16].
Multiplication of the 3q26.3 gene locus causes SOX2
amplification, which has been reported in
glioblastoma, small-cell lung cancer and many squa-
mous cell carcinomas [17–24]. Co-amplification of
SOX2 and Protein Kinase CI (PRKCI) has been re-
ported to be responsible for the CSC phenotype in
lung squamous cell carcinoma [25]. Additionally,
FGF induces SOX2 in osteoblasts [26].
c) SOX2 functions
In pancreatic cancer cells, SOX2 overexpression causes
increased cell proliferation via cyclin D3 induction
[27]. Subsequent SOX2 knockdown causes
transcriptional induction of p21Cip1 and p27Kip1,
resulting in cell cycle arrest and cell growth inhibition
[27]. Similarly, SOX2 silencing inhibits cellular
proliferation in lung squamous cell carcinoma cells
[28]. The upregulation of BMP4, which acts as a
tumor suppressor, is responsible for this inhibition of
proliferation [28]. SOX2 silencing causes a decrease in
cell proliferation and loss of tumorigenicity in
glioblastoma tumor-initiating cells in immunodeficient
mice [29]. SOX2 has also been reported to promote
cellular proliferation in breast, prostate, and cervical
cancers, among others [30–32]. Furthermore, SOX2
has been implicated in the evasion of apoptotic signals
in prostate cancer, gastric cancer and NSCLC [32–34].
SOX2 has been reported to promote invasion, migra-
tion, and metastasis in melanoma, colorectal cancer,
glioma, gastric cancer, ovarian cancer and hepatocellu-
lar carcinoma [20, 35–38]. SOX2 mediates invasive
and migratory phenotypes, in part, through MMP3,
MMP2, and PI3K/AKT/mTOR activations [35, 37, 39].
d) Regulation of SOX2
The ubiquitin-specific protease 22 (USP22) represses
the SOX2 promoter in embryonic differentiation [40].
Activation of EGFR signaling increases SOX2 expres-
sion and self-renewal in prostate CSCs [41]. Further-
more, an EGFR/STAT3/SOX2 signaling pathway has
been reported in murine breast cancer stem cells [42].
In primary melanoma cells, GLI1 and GLI2 have been
reported to bind the proximal SOX2 promoter, indicat-
ing that SOX2 is regulated, in part, by Hedghog-GLI
signaling [43]. The PI3K/Akt signaling pathway has
been shown to be activated in prostate cancer cells
overexpressing SOX2 [44]. By contrast, ovarian adeno-
carcinoma cells overexpressing SOX2 have been re-
ported to possess an inhibited PI3K/Akt signaling
pathway [45]. These conflicting results suggest that
PI3K/Akt modulation may have an important role in
the expression of SOX2.
e) Clinical implications
SOX2 overexpression is correlated with tumor
recurrence, poor prognosis and chemoresistance in
head and neck squamous cell carcinoma [15]. SOX2
overexpression increases tumorigenicity and inhibits
differentiation in neuroblastoma [46]. High SOX2
expression is associated with higher histological
grade in esophageal squamous cancer (p < 0.001)
[47]. A significant correlation (p < 0.001) between
high SOX2 expression and decreasing patient
survival was also established in the same study [47].
In contrast, SOX2 has been shown to correlate with
improved survival and better patient outcome in
lung cancer [48–53]. The expressions of SOX2,
OCT4 and NANOG correlate positively with the
pathological grade of gliomas [54].
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OCT4
a) General properties of OCT4
The POU5F1 gene is located on chromosome 6p21.33
[6, 55]. There are 6 related pseudogenes on
chromosomes 1, 3, 8, 10 and 12 [56], and alternative
splicing results in multiple protein isoforms. The
canonical OCT4 protein sequence contains 360 amino
acids and weighs 38.6 kDa [8]. OCT4, also referred to
as POUF51 and OCT3/4, is another transcription
factor necessary for maintaining pluripotency [57]. The
POU domain is the main active domain for OCT4. The
POU domain is composed of two subdomains, an
amino-terminal POU specific region and a carboxyl-
terminal homeodomain, and both bind DNA through
helix-turn-helix structures [58].
b) OCT4 expression in various cancers
OCT4 is overexpressed in recurrent prostate cancer
tissues [14]. Bioinformatics analysis showed OCT4
overexpression in 9/36 of different solid tumor types
when compared to corresponding normal tissues
[16]. Namely, OCT4 was overexpressed in bladder,
brain, lung, ovarian, pancreatic, prostate, renal,
seminoma and testicular cancers. OCT4
overexpression was observed in 1/4 hematological
cancers—namely, chronic lymphocytic leukemia—in
the same study [16].
c) OCT4 functions
OCT4 works synergistically with SOX2, among
other factors, to regulate transcription. SOX2 and
OCT4 are both activators of genes involved in
pluripotency, including themselves and NANOG,
and repressors of genes involved in differentiation
(e.g., HOXB1, PAX6, MYF5) [59, 60]. SOX2 and
OCT4 interact directly to activate target gene
transcription [61]. OCT4/SOX2 heterodimers bind
the NANOG proximal promoter region to induce
transcription [62, 63].
d) Regulation of OCT4
SOX2 and OCT4 regulate their own transcription by
binding the composite sox-oct elements in the SOX2
and POU5F1 enhancers [64]. In pluripotent stem
cells, Foxm1 directly binds the POU5F1 promoter
−3 kb upstream region [65]. Among others, SALL4,
ESRRB, and PAF1 have been implicated as positive
regulators of OCT4 expression, while TCF3, GCNF,
HIF and CDK2 have been identified as negative reg-
ulators [66].
e) Clinical implications
Like high SOX2 expression, high OCT4 expression
is associated with higher histological grade in
esophageal squamous cancer (p < 0.001) [47]. Both
NANOG and OCT4 overexpressions are associated
with both advanced cancer stage and decreased
survival in oral squamous cell and lung
adenocarcinomas [67].
NANOG
a) General properties of NANOG
The NANOG gene is located on chromosome
12p13.31 [6, 7, 55]. The 2184-nucleotide NANOG
cDNA encodes the NANOG protein [68]. While
there are 11 NANOG pseudogenes [69], only
pseudogene 8 has an open reading frame capable of
producing the functional NANOG protein [69–72].
The canonical NANOG protein has a sequence of
305 amino acids and a mass of 34.6 kDa [8]. Another
isoform, NANOG-delta 48, lacks amino acids 168–
183 and is, consequently, 289 amino acids long [8].
b) NANOG expression in various cancers
Both pluripotent mouse and human stem cell lines
express NANOG mRNA, but NANOG mRNA is
absent from differentiated cells [73]. NANOG
protein levels have been reported to be elevated in
oral squamous cell carcinoma tumor tissues as
compared to corresponding normal tissues (p =
0.014) [74].
c) NANOG functions
NANOG is capable of maintaining embryonic stem
cell pluripotency independently of the LIF-STAT3
pathway, which OCT4 is incapable of doing [68, 73].
NANOG exerts many functions through its tran-
scriptional regulatory activities. NANOG regulates
the cell cycle and proliferation by directly binding
the cyclin D1 promoter [75, 76]. In prostate cancer
cell lines, the induction of NANOG causes the upre-
gulations of CD133 and ALDH1 [77]. NANOG
alone is sufficient to induce SLUG transcription [67].
Furthermore, NANOG is capable of inducing CSC-
like properties in primary p53-deficient mature
mouse astrocytes; however, astrocytes with intact
p53 could not be induced [78]. Some functional re-
dundancy and cooperation between NANOG and
STAT3 have been reported. The two form a complex
in head and neck squamous cell carcinoma cells
[79], and microarray analysis showed that NANOG
also regulated 14 out of the 22 STAT3 target genes
involved in the maintenance of an undifferentiated
state [80].
SOX2, OCT4 and NANOG co-occupy the promoter
regions of at least 353 genes, and NANOG has been
shown to occupy >90 % of the promoter regions
bound by both OCT4 and SOX2 in human embry-
onic stem cells [59]. More explicitly, in >90 % of the
cases where a promoter region is bound by both
OCT4 and SOX2 in human embryonic stem cells,
NANOG is also present.
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d) Regulation of NANOG
In addition to OCT4/SOX2 heterodimers, NANOG is
regulated at a transcriptional level by multiple factors.
GLI1 and GLI2 activate NANOG transcription by
directly binding cis-regulatory sequences of the
NANOG gene in neural stem cells [81]. In mouse
embryonic stem cells, p53 was shown to suppress
NANOG transcription in response to DNA damage.
P53 directly binds the NANOG promoter through
two consensus binding motifs [82]. LIF-induced
STAT3 phosphorylation also results in the upregula-
tion of NANOG in embryonic stem cells [83].
e) Clinical implications
Increased nuclear NANOG expression has been
associated with high-grade subtypes of ovarian can-
cer and poor disease-free survival [84]. Additionally,
NANOG overexpression is correlated with poor
prognoses for colorectal and breast cancer patients,
as well as for ovarian cancer patients [85–87].
BMI1
a) General properties of BMI1
Ensembl identifies the BMI1 gene as located on
chromosome 10p12.2. The BMI1 protein is
composed of 326 amino acids and has a mass of
36.9 kDa [8]. BMI1 is a member of the polycomb
repressive complex 1 (PRC1), which also includes
Mel-18, Mph1/Rae28, M33, Scmh1, and Ring 2. The
polycomb repressive complex 2 (PRC2) is comprised
of EED, EZH, Sux12 and YY1 [88].
b) BMI1 expression in various cancers
BMI1 expression levels have been reported to be
high in many tissues, including the brain, esophagus,
kidney, lungs, and blood, among others [89]. BMI1
levels are also elevated in various solid tumor-
forming cancers, among them neuroblastoma and
bladder cancer [90, 91].
c) BMI1 functions
BMI1 is involved in the maintenance and/or self-
renewal of many stem cell types, including embry-
onic, neural, hematopoietic and prostate [92–95].
BMI1 promotes the proliferation of leukemic stem
cells in mouse models [96], and BMI1 activates the
self-renewal ability of neural stem cells [97].
BMI1 is directly responsible for the regulation of
multiple targets. BMI1 regulates the tumor
suppressors p16INK4a and p14ARF [98, 99]. BMI1
also directly binds the PTEN promoter, resulting in
the activation of the PI3K/AKT pathway and
subsequently SNAIL stabilization and EMT
induction [100]. Additionally, BMI1 directly
occupies the CDH1 promoter, causing E-cadherin
repression [100].
In endometrial cancer cells, the loss of BMI1 results
in the reduced expression of SOX2 and KLF4 [101].
CD133+ breast CSCs with high SLUG expression
have been shown to also have high BMI1 expression
[102]. Furthermore, BMI1 cooperates with TWIST1
to promote cancer dedifferentiation and metastasis
[103]. BMI1 overexpression correlates with NANOG
overexpression, high-grade status and increased self-
renewal in breast adenocarcinomas [104].
d) Regulation of BMI1
Multiple major regulatory pathways, including Akt,
Wnt and Notch, contribute to the regulation of
BMI1 [105]. Additionally, the Hedgehog pathway
activates BMI1 in breast stem cells [106].
e) Clinical implications
Elevated BMI1 RNA levels have been correlated
with more advanced chronic myeloid leukemia
status [96, 107]. Increased levels of BMI1 are
correlated with poor prognoses in head and neck
cancers [103], including in nasopharyngeal
carcinoma patients [108]. BMI1 is further
correlated with radio- and chemoresistance in head
and neck squamous cell carcinomas and is
considered to be a predictive factor for overall
survival [109]. In glioma, BMI1 expression inversely
correlates with survival and positively correlates
with poor prognosis [110]. In non-Hodgkin B-cell
lymphoma patients, BMI1 expression is associated
with poor outcome as well [111].
CSC markers’ associations with drug resistance
Each of the CSC markers discussed above are implicated
in resistance to cancer treatments. In breast cancer, SOX2
silencing restores tamoxifen sensitivity [112]. NANOG
overexpression, likewise, increases drug resistance in
breast cancer cell lines [77]. Lung adenocarcinoma cell
lines are sensitized to erlotinib by shRNA-knockdown of
SOX2 [50]. Overexpressions of NANOG and OCT4 also
afford lung adenocarcinoma cells a high tolerance to cis-
platin [67]. The overexpression of NANOG promotes cis-
platin resistance in esophageal cancer [113], and siRNA-
knockdown of NANOG increases sensitivity to cisplatin
[114]. The elevated expressions of NANOG and OCT4
correlate with cisplatin resistance and recurrence in oral
squamous cell carcinoma [115]. SOX2 has been impli-
cated in paclitaxel resistance in prostate cancer cell lines
[44]. Docetaxel sensitivity is increased in prostate cancer
cells by silencing BMI1 [116]. Ovarian CSCs are more
resistant to cisplatin and paclitaxel when BMI1 is overex-
pressed [117], and targeting BMI1 sensitizes ovarian can-
cer cells to cisplatin [118]. Furthermore, CD44+/CD24+
pancreatic cancer cells expressing high levels of BMI1 are
largely resistant to gemcitabine [119].
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Yin Yang 1 (YY1) and its relationship with CSC
transcription factors
General characteristics of YY1
Yin Yang 1 (YY1) is an ubiquitously expressed zinc-
finger transcription factor encoded by the 23 kb YY1
gene [120–124]. Comprised of 414 amino acids, YY1 ex-
erts various cellular functions, including transcriptional
regulation, cell proliferation, chromatin remodeling and
apoptosis [124–128]. YY1 regulates multiple targets, in-
cluding ERBB2, p53, caspases and HDACs, which are
implicated in cancer progression [127].
YY1 is overexpressed in many types of cancer, including
metastatic breast cancer [129, 130], colon cancer [131],
gastric cancer [132] and prostate cancer [133]. Patterns of
YY1 protein expression levels in human cancers have been
reviewed previously [134]. The enrichment of binding
sites for YY1 and NANOG was identified in the interac-
tomes of both SOX2 and POU5F1 [135]. Additionally,
YY1 upregulates NANOG in gastric cancer [136]. YY1 has
been previously reported to directly interact with embry-
onic ectoderm development (EED), a protein of the same
PcG family as BMI1 [137].
YY1 and its relationship to CSC transcription factors
There exist similar patterns of overexpression in various
cancerous tissues between the four CSC markers (SOX2,
OCT4, BMI1 and NANOG) and YY1. For example, the
overexpressions of YY1 [133], SOX2 and OCT4 [14] in
prostate cancer cell lines have been reported. These find-
ings suggested that there may be a functional correlation
between YY1 and the CSC markers (Fig. 1). Furthermore,
the binding site enrichment and interactions with NANOG
and EED suggest that YY1 may be associated with the CSC
transcription factors [135–137].
Data mining from proteomic datasets
Publicly available proteomics datasets were used to assess
whether YY1, SOX2, OCT4, NANOG and BMI1
expressions correlated in both solid tumors (n = 16) and
hematological malignancies (n = 1) [138].
1. SOX2, OCT4, NANOG and BMI1 were chosen as
representative CSC markers because of their well-
documented roles in stem cell maintenance as well
as data availability [5, 59, 92–95].
The Human Protein Atlas’ Cancer Atlas feature
provides antibody staining information for many
proteins in various cancerous tissues [139]. The
antibodies used by the Human Protein Atlas for this
staining analysis are summarized in Table 1. The
Cancer Atlas feature was interrogated to assess the
antibody staining of YY1, SOX2, OCT4, NANOG
and BMI1 in different cancer types. In each case, the
protein of interest was searched in the Cancer Atlas.
The resulting “staining overview” presented the
antibody staining profile, which differentiated stains
into high, medium, low or not detected groups, for
the protein in twenty types of cancers, namely,
breast, carcinoid, cervical, colorectal, endometrial,
glioma, head and neck, liver, lung, lymphoma,
melanoma, ovarian, pancreatic, prostate, renal, skin,
stomach, testis, thyroid and urothelial cancers. The
three cancers with sample sizes fewer than
four—carcinoid, head and neck, and thyroid—were
discarded, bringing the total types of cancers
considered herein to seventeen.
2. Example profile
SOX2 staining qualified as 0/12 high, 1/12 medium, 9/
12 low and 2/12 not detected in breast cancer. In this
case, 12 different tissues were stained from 12 different
patients. A binary system was then applied such that
only high or medium scores were considered positive
staining. To assess the percentage of positive staining,
the number of “positive” (high or medium) stains was
divided by the total number of stains performed. In the
SOX2 case presented above, (0 high +1 medium)/12
stains yields 1/12 positive staining.
Fig. 1 Hypothesized cross-talk between YY1 and CSC transcription factors. This model reflects prior findings and proposed linkages between YY1
and CSC markers
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3. Example analysis
Breast cancer can be used as an example to illustrate
the complete process used by us for analysis for one
cancer type. The Human Protein Atlas’ Cancer Atlas
reported that YY1 antibody HPA001119 yielded 2
high, 5 medium, 1 low and 1 not detected stains in
this type of cancer. Consequently, high and medium
scores comprised 7 out of a total 9 stains. In this
case, 78 % of the stains were above the binary
threshold and considered positive staining. YY1
antibody CAB009392 yielded 0 high, 6 medium, 5
low and 0 not detected stains, so the positive
staining was 6/11 or 55 %. As previously described,
the SOX2 antibody CAB010648 profile was 0 high, 1
medium, 9 low and 2 not detected stains. Only 1/12
stains exceeded the binary threshold for 8 % positive
staining. NANOG antibody CAB019380 was never
detected in breast cancer and had 0 % positive
staining. By these same processes, it was determined
that BMI1 antibody HPA030472 had 10/11 (91 %),
BMI1 antibody CAB011120 had 8/10 (80 %), OCT4
antibody CAB025600 had 11/11 (100 %) and OCT4
antibody CAB026380 had 5/9 (55 %) positive
staining.
4. Antibody selection
We have selected only one antibody staining profile
for each protein that was stained by two different
antibodies. This choice was based on the
recommendation of the Human Protein Atlas itself
and was performed for the sake of simplifying ensuing
analyses. The final antibodies used were YY1 antibody
HPA001119, SOX2 antibody CAB010648, NANOG
antibody CAB019380, BMI1 antibody CAB011120
and OCT4 antibody CAB026380 (Table 1). Of note,
YY1 antibody HPA01119 appears to show cross-
reactivity with related protein YY2 (based on an 80 %
amino acid homology), and thus, cross-reactivity be-
tween family members by the various antibodies used
must be considered with the results. It is impossible
to ignore the possibilities that the noted expression
correlations are instead between YY2 and CSC
transcription factors, or that there is a functional
redundancy between YY1 and YY2 that cannot be
distinguished. To that end, the development of YY1-
specific antibodies is necessary to validate these
findings in vitro. Western blots should be conducted
to confirm these findings experimentally.
5. Further analyses
These procedures were repeated for each antibody
in each type of cancer and used to produce binary
expression graphs and corresponding statistical
analyses. The example breast cancer binary
frequency of the protein expression graph was used
as a prototype (Fig. 2). The binary expression graphs
only show the positive staining derived from the
Table 1 Selected antibodies characteristics
YY1 antibody
HPA001119
SOX2 antibody
CAB010648
NANOG antibody
CAB019380
BMI1 antibody
CAB011120
OCT4 antibody
CAB026380
Provider Atlas Antibodies,
Sigma-Aldrich
Chemicon SDIX Upstate SDIX
Product name HPA001119 AB5603 2929.00.02 05–637 3542.00.02
Host species Rabbit Rabbit Rabbit Mouse Rabbit
Clonality pAb pAb msAb mAb msAb
Antigen Recombinant
protein fragment
Synthetic peptide Genetic
immunization
Recombinant
protein
Genetic
immunization
Cross reactivity YY2 (80 %) N/A N/A N/A N/A
Fig. 2 Example of a represented binary percentages of positive
staining (frequency of protein expression) in breast cancer. Staining
was categorized as high, medium, low or not detected for each
antibody by the Human Protein Atlas (proteinatlas.org). For the
purposes of applying a binary system of enumeration, only high or
medium scores were considered positive staining. The number of
these positive stains was divided by the number of total stains
performed to ascertain the percentage of positive staining. For
example, for YY1 antibody HPA001119, there were 2 high and 5
medium scores. That comprises 7 out of a total 9 stains for a total of
78 % positive staining. The graph compares these percentages of
positive staining for each antibody—YY1 antibody HPA001119, YY1
antibody CAB009392, SOX2 antibody CAB010648, NANOG antibody
CAB019380, BMI1 antibody HPA030472, BMI1 antibody CAB011120,
POU5F1 antibody CAB025600 and POU5F1 antibody CAB026380—in
breast cancer
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high and medium staining of each antibody in breast
cancer. Two-factor without replication analysis of
variance was applied to analyze the source of vari-
ation between the different antibody staining figures.
Pearson correlations were performed to compare the
staining of each antibody of each marker to the
others. Post-hoc t-tests also assessed the significance
between YY1 and CSC marker expressions. From
these data, patterns of YY1, SOX2, OCT4, NANOG
and BMI1 protein expressions were elucidated and
evaluated.
Clustered expression analyses
Through the grouping of marker expression patterns,
our analyses identified four distinct tiers of cancers
(Additional file 1: Figure S1). Initially, two distinct
dynamics were identified: in clusters one and two, YY1
and SOX2 expressions share an inverse relationship,
while in clusters three and four, YY1 and SOX2 expres-
sions have a strong direct correlation. The two types of
relationship between YY1 and SOX2 expression appear
to dictate distinctive patterns of expression of BMI1 and
OCT4. These patterns of expression between YY1,
SOX2, OCT4 and BMI1 were used to classify the four
tiers.
Tier 1
The first group consists of prostate, lung, cervical, endo-
metrial and ovarian cancers as well as glioma. This
group shows low YY1 expression with concomitant high
SOX2, BMI1 and OCT4 expressions (Fig. 3). Of note,
Fig. 3 a Frequency of Protein expression. Antibody staining for glioma, prostate, lung, cervical, endometrial, and ovarian cancers (Tier 1). SOX2
and OCT4 have a strong direct correlation (R2 = 0.99). b Hypothetical functional dynamic of CSC-related transcription factors. Correlations of the
frequency of protein expression in a segregated malignancies tier
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comparison of SOX2 and OCT4 expressions yields an
R2 value of 0.99, indicating a strong direct correlation.
Tier 2
Tier two, characterized by high YY1 and low SOX2, is
found in skin, testis and breast cancers. SOX2 and BMI1
have a strong inverse correlation (R2 = −1.0) and YY1
has a direct correlation with OCT4 expression (R2 = 0.7).
These findings show an overall pattern of high YY1, low
SOX2, high BMI1 and high OCT4 (Fig. 4).
Tier 3
Liver, stomach, renal, pancreatic and urothelial cancers
make up the third tier. This cluster has low YY1 and low
SOX2 expressions. SOX2 and OCT4 have a strong in-
verse correlation (R2 = −0.9), and BMI1 and OCT4 also
have an inverse correlation (R2 = −0.7). This group has a
molecular signature of low YY1 and SOX2 with high
BMI1 and OCT4 (Fig. 5).
Tier 4
The fourth tier has high YY1 and high SOX2. This group
consists of colorectal cancer, lymphoma and melanoma.
YY1 and SOX2 both share strong direct correlations
with OCT4 expression (R2 = 1.0 and 0.8, respectively). In
this case, YY1, SOX2 and OCT4 all have high expres-
sions while BMI1 has low expression (Fig. 6).
Overarching results
Taken together, tiers one and two show a strong inverse
correlation between YY1 and SOX2 (R2 = −0.9). On the
contrary, tiers three and four show a strong direct
Fig. 4 a Frequency of Protein expression. Antibody staining for skin, testis and breast cancers (Tier 2). YY1 is positively associated with OCT4 (R2 =
0.7), while SOX2 is negatively associated with BMI1 (R2 = −1.0). b Hypothetical functional dynamic of CSC-related transcription factors. Correlations
of the frequency of protein expression in a segregated malignancies tier
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correlation between YY1 and SOX2 expressions (R2 = 0.8).
These associations were the initial basis for the distinc-
tions among the four tiers. The tiers were then further
subdivided based on the specific frequency of expression
patterns of BMI1 and OCT4. When tiers three and four
are grouped together, such that the results from liver,
stomach, renal, pancreatic, urothelial cancers, lymphoma
and melanoma are pooled, there is also a strong inverse
correlation between YY1 and BMI1 expressions (R2 =
−0.7). YY1 expression correlates strongly and differentially
with the CSC markers’ expression in the different tiers.
Conclusions, implications and speculations
YY1 frequency of expression was associated with the
SOX2, BMI1 and OCT4 frequency of expression across
many cancers, though the type of association varied. The
differential patterns of the four markers’ expressions
among the different tiers can be explained by the dual
nature of YY1’s activities as both an activator and a re-
pressor and in a direct or an indirect manner. We have
examined the putative regulatory regions (promoters) of
BMI1, SOX2, POU5F1 (OCT4) and YY1 for potential
YY1 binding sites and reciprocal control of each other in
a combinatorial matrix by using SABioscience’s Text-
Mining Application [140] and data from the University
of California, Santa Cruz (UCSC) Genome Browser
[141] in order to define predicted binding sites associa-
tions of transcription factors to their regulatory regions.
Our analysis demonstrated the presence of putative YY1
binding sites on all of the regulatory regions of the inter-
rogated transcription factors (i.e., BMI1, SOX2, OCT4)
including YY1 itself. However, none of the putative tran-
scription binding sites for BMI1, SOX2, OCT4 were
found on the YY1 or on each other’s regulatory regions.
Fig. 5 a Frequency of Protein expression. Antibody staining for liver, stomach, renal, pancreatic and urothelial cancers (Tier 3). There are
significant negative correlations between SOX2 and OCT4 (R2 = −0.9) as well as between BMI1 and OCT4 (R2 = −0.7). b Hypothetical functional
dynamic of CSC-related transcription factors. Correlations of the frequency of protein expression in a segregated malignancies tier
Kaufhold et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:84 Page 9 of 14
Noteworthy, a strong association (predicted binding site)
was noted between NF-κB on the YY1 regulatory region
and also between YY1 on the BMI1 promoter, suggesting
a plausible transcriptional control by these factors.
The transcriptional association of YY1 on the regula-
tory regions of BMI1, SOX2, OCT4 and YY1 suggests a
multi-dynamic regulatory control of expression. There is
an NF-κB-mediated induction of expression of YY1 that
can: a) inhibit the transcription of BMI1 and increase
the expression of SOX2, resulting in up-regulation of
OCT4 (e.g., Tier 1, Tier 2 and Tier 4 of the clustered
groups); or b) activate the transcription of BMI1 and de-
crease the expression of SOX2, resulting in down-
regulation of OCT4; or c) directly activate transcription
of OCT4 (e.g., Tier 3 of clustered groups). Overall, the
majority of the malignancies examined in this study have
YY1 as a potential transcriptional repressor acting on
CSCs-associated transcription factors.
It is important to note that the association of YY1 and
CSC transcription factors was based on analysis of expres-
sion patterns on whole tumor tissues and not on the CSC
subsets. Clearly, additional studies are necessary to deter-
mine whether the associations seen on whole tumor tis-
sues is also found in the CSC subsets of the various
cancers examined herein. The validation of YY1’s associ-
ation with CSC markers and their functional roles in CSC
regulation may provide new insights on the role of YY1 in
carcinogenesis and its potential as a therapeutic target.
Fig. 6 a Frequency of Protein expression. Antibody staining for colorectal cancer, lymphoma and melanoma (Tier4). There are strong positive
associations between YY1 and OCT4 (R2 = 1.0) as well as between SOX2 and OCT4 (R2 = 0.8). b Hypothetical functional dynamic of CSC-related
transcription factors. Correlations of the frequency of protein expression in a segregated malignancies tier
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Additional file
Additional file 1: Figure S1. Clustered Expression Association. Results
were cluster-associated in 4 groups (tiers) based on the percentage of
positive staining (Frequency of protein expression). Green boxes, ≧ 50 %
positive staining. Blue boxes, <50 % positive staining. (JPG 66 kb)
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